The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs

Journal of Rheumatology

Volumn 26, Issue 2, 1999, Pages 325-330

  Rahman, Proton ^a   Gladman, Dafna D ^a,b   Urowitz, Murray B ^a   Yuen, Kenneth ^a   Hallett, David ^a   Bruce, Ian N ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Antimalarials; Corticosteroids; Lipids; Prevention; SLE; Treatment

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; CHOLESTEROL; CORTICOSTEROID; HYDROXYCHLOROQUINE; PREDNISONE;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIMALARIALS; ANTIRHEUMATIC AGENTS; CHLOROQUINE; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; HYDROXYCHLOROQUINE; HYPERCHOLESTEROLEMIA; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREDNISONE; RETROSPECTIVE STUDIES;

EID: 0032900519     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Rynes RI. Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol 1997;36:799-805.
2. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996; Suppl 1:S16-S22.
3. Urowitz MB, Bookman AAM, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality in systemic lupus erythematosus. Am J Med 1976;60:221-5.
4. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997;145:5:408-15.
5. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol 1987;14 Suppl 13:223-6.
6. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-9.
7. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine in coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994;20:661-5.
8. Beynen A, van der Molen AJ, Geelen MJH. Inhibition of hepatic cholesterol biosynthesis by chloroquine. Lipids 1981;16:6:472-4.
9. Goldstein JL, Brown MS. The LDL pathway in human fibroblasts: a receptor-mediated mechanism for the regulation of cholesterol metabolism. Curr Top Cell Regul 1976;11:147-81.
10. Matasuzama Y, Hostetler KY. Studies in drug-induced lipidosis: subcellular localization of phospholipid and cholesterol in the liver of rats treated with chloroquine o-4,4-bis (diethylamnoethoxy) α,β-diethyldihenylethane. J Lipid Res 1980;21:202-14.
11. Oram JF, Albers JJ, Cheung MC, Bierman EL. The effects of subtractions of high density lipoprotein on cholesterol efflux from cultured fibroblasts. J Biol Chem 1981;256:16:8348-56.
12. Quatraro A, Consoli G, Magno M, et al. Hydroxychloroquine in decompensated treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann Intern Med 1990;112:678-81.
13. Wallace DJ, Metzger AL, Stetcher V, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of corticosteroids on lipids. Am J Med 1990;89:322-6.
14. Hodis HN, Quismorio FP, Wickham E, Blankenhorn DH. The lipid lipoprotein and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993;20:661-5.
15. Petri M, Lakatta C, Magder L, Goldman DW. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994;96:254-9.
16. Kavanaugh A, Adams-Huet B, Jain R, Denke M, McFarlin J. Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double blind, randomized, placebo controlled, pilot study in patients with systemic lupus erythematosus. J Clin Rheumatol 1997;3:1:3-8.
17. Nossen JO, Rustan AC, Barnard T, Drevon CA. Inhibition by chloroquine of the secretion of very low density lipoproteins by cultured rat hepatocytes. Biochim Biophys Acta 1984;803:11-20.
18. Ettinger WH, Hazzard WR. Prednisone increases very low density lipoprotein and high density lipoprotein in healthy men. Metabolism 1988;37:11:1055-8.
19. Ettinger WH, Goldberg AP, Applebaum-Bowden D, Hazzard WR. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 1987;83:503-8.
20. Hearth-Holmes M, Baethge BA, Broadwell L, Wolf RE. Dietary treatment of hyperlipidemia in patients with systemic lupus erythematosus. J Rheumatol 1995;22:3:450-4.